UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000718
Receipt number R000000857
Scientific Title Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)
Date of disclosure of the study information 2007/05/25
Last modified on 2021/11/15 23:00:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)

Acronym

OGSG 0603

Scientific Title

Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)

Scientific Title:Acronym

OGSG 0603

Region

Japan


Condition

Condition

advanced/recurrent colon cancer or rectal cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To test the feasibility of Carmazepin therapy and to evaluate whether Carmazepin has the protective and/or prophylactic effects against peripheral nerve syndrome due to FOLFOX therapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To test the feasibility of Carmazepin therapy and to evaluate whether Carmazepin has the protective and/or prophylactic effects against peripheral nerve syndrome due to FOLFOX therapy

Key secondary outcomes

Median dose of L-OHP, nerve disorder at the end of FOLFOX, Course, PFS and TTF, Response Rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Carbamazepin is administered during FOLFOX therapy.
Carbamazepin tablet 100mg, 200mg or granule including Car. 500mg in 1000mg

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) colon cancer or rectal cancer, histologically
(2) eligible in the both patients with prior therapy and without any prior therapy
(3) eligible in the both patients with and without measurable lesions
(4) age between >= 20 years old and <= 75 years old
(5) with the expected survival period more than 12 weeks
(6) more than 4 weeks after surgical operation
(7) Performance Status (ECOG) 0-1
(8) without any disorder in the important organs and with good results of the
Examinations seven days before the registeration
WBC: 3,000 &#8211; 12,000 /mm3
Neutrocyte: more than 1,500/mm3
Platelet: more than 100,000/mm3
s Total Bil: within 1.5 times of normal range
sAST, sALT, sALP: within 2.5 times of normal range
s Creatinin: within the normal range
(9) written informed consent
(10) patients who can take food orally

Key exclusion criteria

(1) Patients who received transfusion, blood components or GCSF within seven days Before registration
(2) with brain metastasis
(3) with much cavity fluid to be removed
(4) with active double cancer
(5) allergy against medicines
(6) uncontrolled Hypertension
(7) receiving digitalis
(8) uncontrolled DM
(9) active infectious disease
(10) watery diarrhea
(11) disorder on EKG
(12) severe respiratory diseases (interstitial pneumonitis, pulmonary fibrosis, Severe pulmonary emphysema)
(13) psychiatric disorder
(14) fresh bleeding on the digestive tract
(15) sensory nerve disorder
(16) pregnant and/or nursing women
(17) driving a complicated mechanism or vehicle
(18) Doctors' stop not to be registered

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Katou

Organization

Minoo municipal hospital

Division name

Dpt.Surgery

Zip code


Address

562-8562 5-7-1 Kayano,Minoo-shi,Osaka 562-8562

TEL

072-728-2001

Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Sakai Cdty Hospital

Division name

Director

Zip code


Address

1-1-1,Minamiyasuicho,Sakai-ku,Sakai, 590-0064

TEL

072-221-1700

Homepage URL


Email



Sponsor or person

Institute

OGSG

Institute

Department

Personal name



Funding Source

Organization

NPO Osaka Chinical Study Supporting Organization

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 05 Month 25 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2006 Year 07 Month 24 Day

Date of IRB


Anticipated trial start date

2006 Year 08 Month 01 Day

Last follow-up date

2007 Year 07 Month 01 Day

Date of closure to data entry

2007 Year 07 Month 01 Day

Date trial data considered complete

2007 Year 12 Month 01 Day

Date analysis concluded

2008 Year 01 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 05 Month 17 Day

Last modified on

2021 Year 11 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000857


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name